VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

Erika P Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz, Seth A Wander, Michael Danso, Dongrui R Lu, Julia Perkins Smith, Yuan Liu, Lana Tran, Sibyl Anderson, Mario Campone

Open source

DOI: 10.1080/14796694.2024.2377530
Published: 2024-07-29
Container: Future Oncology
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2024.2377530,
  title = {VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer},
  author = {Erika P Hamilton and Cynthia Ma and Michelino De Laurentiis and Hiroji Iwata and Sara A Hurvitz and Seth A Wander and Michael Danso and Dongrui R Lu and Julia Perkins Smith and Yuan Liu and Lana Tran and Sibyl Anderson and Mario Campone},
  year = {2024},
  journal = {Future Oncology},
  doi = {10.1080/14796694.2024.2377530},
  url = {https://doi.org/10.1080/14796694.2024.2377530}
}

RIS

TY  - JOUR
TI  - VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
AU  - Erika P Hamilton
AU  - Cynthia Ma
AU  - Michelino De Laurentiis
AU  - Hiroji Iwata
AU  - Sara A Hurvitz
AU  - Seth A Wander
AU  - Michael Danso
AU  - Dongrui R Lu
AU  - Julia Perkins Smith
AU  - Yuan Liu
AU  - Lana Tran
AU  - Sibyl Anderson
AU  - Mario Campone
PY  - 2024
JO  - Future Oncology
DO  - 10.1080/14796694.2024.2377530
UR  - https://doi.org/10.1080/14796694.2024.2377530
ER  -

APA

Hamilton, E. P., Ma, C., Laurentiis, M. D., Iwata, H., Hurvitz, S. A., Wander, S. A., Danso, M., Lu, D. R., Smith, J. P., Liu, Y., Tran, L., Anderson, S., & Campone, M. (2024). VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future Oncology. https://doi.org/10.1080/14796694.2024.2377530

Source records

crossref · retrieved 2026-09-26T10:42:44.729Z